The global breast reconstruction surgery and treatment market is forecasted to expand at 5.9% CAGR to reach a market valuation of USD 1.61 Billion by the end of 2033, up from USD 853.9 Million that was recorded for 2022.
The global breast reconstruction surgery and treatment market is anticipated to be driven by an increase in breast cancer prevalence, an increase in the number of breast reconstruction procedures, and a surge in demand for acellular dermal matrix.
| Attribute | Details |
|---|---|
| Breast Reconstruction Surgery and Treatment Market Size (2023) | USD 901.3 Million |
| Forecasted Market Value (2033) | USD 1.61 Billion |
| Value CAGR (2023 to 2033) | 5.9% |
| Collective Value Share: Top 5 Countries (2022) | 64.1% |
| Key Market Players | Mentor Worldwide LLC (Johnson & Johnson); Allergan Aesthetics (An AbbVie Company); Sientra; POLYTECH Health & Aesthetics GmbH; GC Aesthetics; Sebbim; Establishment Labs S.A.; Integra Lifesciences; RTI Surgical Holdings; Idel Implant Incorporated; Laboratoires Arion; Silimed; Guangzhou Wanhe Plastic Material Co., Ltd.; Cereplas; Hansbiomed; PMT Corporation; and PFM Medical |
Breast reconstruction, also referred to as breast augmentation, entails remodeling of the areola and nipple. Women typically undergo breast reconstruction. There are three types of breast reconstruction: autologous tissue reconstruction, implants/prosthetic reconstruction, and tissue and implant reconstruction.
Breast reconstruction with artificial implants is referred to as implants/prosthetic breast reconstruction. It is referred to as autologous tissue breast reconstruction when a portion of tissue from another region of the body is used to reconstruct the breast. Either autologous tissue reconstruction, implants/prosthetic reconstruction, or both types of reconstruction are used for breast augmentation.
Women who have undergone breast reconstruction deal with numerous issues.
Breast reconstruction using silicone and saline is frequently connected with problems. Breast reconstruction is typically done for cosmetic purposes or to restore breast volume that has been lost due to pregnancy, weight loss, or mastectomy for breast cancer. The best choice for breast reconstruction is breast reconstruction surgery.
When the entire breast or a portion of the breast is removed, breast reconstruction is performed.
They assist in coping with breast loss brought on by cancer and are also utilized for cosmetic purposes. During breast reconstruction surgery, the patient should have access to enough privacy.
According to Future Market Insights, the global market has huge growth potential due to the rising prevalence of breast cancer.
Exclusive Offer: 30% Off on Regional Reports
Get a free sample report and customize your regions for a 30% discount on your regional report!
The market for breast reconstruction surgery and treatment expanded at a CAGR of 4.6% during the historic period (2017 to 2022) and reached a market value of USD 853.9 Million in 2022.
The global market for breast reconstruction surgery and treatment accounts for around 1.5% of the global cosmetic surgery market valued at around USD 55.6 Billion in 2022.
The global market for breast reconstruction surgery and treatment is being driven by ongoing improvements in breast reconstruction techniques that improve implant positioning accuracy and shorten recovery times and discomfort. In the coming years, the adoption of ADMs (acellular dermal matrix) is projected to outpace that of breast implants due to the incorporation of cutting-edge technology, such as the conversion from a two-step to a single-step breast reconstruction method.
The rising incidence of breast cancer worldwide and the rise in the number of breast reconstruction treatments are anticipated to boost the global market for breast reconstruction surgery and treatment.
The global market is predicted to expand 1.8X its current size by the end of 2033.
| Market Statistics | Details |
|---|---|
| Jan-Jun (H1), 2021 (A) | 4.41% |
| Jul-Dec (H2), 2021 (A) | 5.57% |
| Jan-Jun (H1),2022 Projected (P) | 4.35% |
| Jan-Jun (H1),2022 Outlook (O) | 4.59% |
| Jul-Dec (H2), 2022 Outlook (O) | 6.03% |
| Jul-Dec (H2), 2022 Projected (P) | 5.43% |
| Jan-Jun (H1), 2023 Projected (P) | 4.91% |
| BPS Change : H1,2022 (O) - H1,2022 (P) | 23↑ |
| BPS Change : H1,2022 (O) - H1,2021 (A) | 17↑ |
| BPS Change: H2, 2022 (O) - H2, 2022 (P) | 60↑ |
| BPS Change: H2, 2022 (O) - H2, 2021 (A) | 46↑ |
After a mastectomy, some women choose to have breast reconstruction surgery. Others avoid it because they don't know about it or because they have other health issues, like obesity, skin-thinness, or alterations in blood flow dynamics.
These women have access to breast reconstruction alternatives like custom breast prostheses and going flat. Additionally, for patients who have had a single mastectomy, a personalized breast prosthesis can give symmetry with the intact breast and match the woman's exact contour.
This prosthesis costs from USD 100 and USD 500 for high-quality goods, which is significantly less than breast reconstruction. However, the market for breast reconstruction surgery and treatments is significantly constrained by alternatives, notably non-surgical methods.
The market for breast reconstruction surgery and treatments may see significant increase because of the introduction of 3D-printed implants. German companies BellaSeno and Evonik have joined to develop 3D breast implant technology.
Senella breast scaffolds from BellaSeno will be composed of Resomer bioresorbable polymer from Evonik, replacing silicone implants, which have raised significant safety concerns.
The first human clinical studies utilising the Senella scaffolds were going to start in Germany in 2019, according to BellaSeno and Resomer plans. Evonik has also made their Resomer polymer available for use in commercial and clinical applications.
The scaffolds, which are constructed from liposuctioned human fat, are designed to direct the development of healthy tissue. This product is meant to be used after surgery for augmentation, reconstruction, or revision. This is gradually absorbed by the body and replaced with native breast tissue.
Check Free Sample Report & Save 40%!
Select your niche segments and personalize your insights for smart savings. Cut costs now!
| Country | The USA |
|---|---|
| Market Share (2023) | 32.0% |
| Market Share (2033) | 32.1% |
| BPS Analysis | 9 |
| Country | Brazil |
|---|---|
| Market Share (2023) | 15.0% |
| Market Share (2033) | 15.5% |
| BPS Analysis | 42 |
| Country | Germany |
|---|---|
| Market Share (2023) | 5.9% |
| Market Share (2033) | 6.0% |
| BPS Analysis | 2 |
| Country | Mexico |
|---|---|
| Market Share (2023) | 5.5% |
| Market Share (2033) | 5.4% |
| BPS Analysis | -9 |
| Country | South Korea |
|---|---|
| Market Share (2023) | 5.2% |
| Market Share (2033) | 5.5% |
| BPS Analysis | 35 |
The United States is set to hold a share of around 32.0% of the global market in 2023.
The market is expanding in the United States as a result of high incidence of breast cancer, rising breast augmentation operations, and developed healthcare infrastructure.
For instance, breast augmentation was one of the top five cosmetic surgery treatments in the United States in 2020, according to the American Society of Plastic Surgeons' 2020 report. It is projected that the region's breast implant market will rise due to the rising incidence of breast cancer. For instance, GLOBOCAN 2020 study reveals that there have been 253,465 new cases of breast cancer in the USA region.
Germany is set to hold a share of 5.9% of the global market in 2023.
The rising prevalence of breast cancer is the primary factor influencing the regional market. For instance, according to World Health Organization, in 2020 around total 69,697 new cases of breast cancer were found in Germany. Due to the rising incidence of breast cancer worldwide, there is a strong need for breast reconstruction surgeries. Because of rising hereditary diseases in women, rising healthcare costs, and changes in government policy, breast reconstruction surgery and treatment is becoming more common.
China is set to expand at a CAGR of 3.3% over the forecast period.
The rise in awareness of breast reconstruction surgery and the fast rising breast cancer population are both responsible for the growth. For instance, the NCBI data revealed that there were about 303,600 new instances of breast cancer and 70,400 fatalities from the disease in China.
Furthermore, according to a similar source, the incidence rate and death rate in China are predicted to rise by 2030 due to changing demographics and hazards. More than 76.5% of women preferred breast reconstruction following mastectomy, according to a research by a similar source. As a result, the market is anticipated to increase significantly during the next years.
Tissue expanders are expected to hold a market share of 64.5% in 2023. After mastectomy tissue expanders are utilized to increase the amount of tissue. These products are placed during mastectomy or in after the patient have cured and finished cancer treatment in second surgery.
Tissue expanders are safe and effective product choose by patients. It is a desirable option since there is no donor defect, the recovery period is shorter, there is less chance of morbidity, and women can choose the size of the reconstructed breast. These benefits of it is anticipated for segment growth.
As per procedures, the market has been segmented into immediate, delayed, and revision. The immediate procedure segment is set to hold 30.1% revenue share in 2023.
In order to reduce the need for subsequent procedures and the risks involved with so surgeries, there is evidence that suggests rapid breast reconstruction is better to delayed breast reconstruction. It has been demonstrated that immediate breast reconstruction reduces recovery time, costs, and improves quality of life and psychological wellbeing.
After a mastectomy, people who still have the appropriate amounts of skin and nipple make suitable candidates for rapid breast reconstruction with a conventional implant. Rapid reconstruction after a mastectomy with skin preservation yields the best cosmetic results. These affirmatory factors are expected to propel the segment growth.
Bilateral is expected to hold a market share of 62.23% in 2023. Women who choose to have bilateral preventative mastectomy or those who have unilateral breast cancer and a high risk of acquiring a contralateral malignancy may all benefit from bilateral breast reconstruction. Women may think about bilateral breast reconstruction in this situation in an effort to enhance their external attractiveness and ultimately enhance their internal sense of attractiveness and femininity.
One benefit of bilateral breast reconstruction is that the patient's reconstructed breast does not have to match the contralateral, native breast; rather, the patient's reconstructed breast can be different from the contralateral, native breast. This benefit of it is expected to lead the segment.
Hospitals are expected to hold a market share of 60.9% in 2023. A growth of hospitals around the world is to blame for the segment's domination. For instance, hospitals account for 80% of the Indian healthcare market, according to the Athar Institute of Health Management & Studies. According to The Canadian Encyclopedia, there are also 193 private hospitals and 706 public hospitals in Canada.
Medical tourism has increased globally as well. As medical tourism grows, it is projected that hospitals' medical facility standards would improve. The abovementioned variables are expected to have a substantial impact on the hospitals segment's growth during the projection period.
The breast reconstruction surgery and treatment market is competitive and has several established companies. To increase their market share, numerous players use tactics like geographic growth, mergers and acquisitions, collaborations, and the launch of new products. Players in both the global and local markets profit from a sizable distributor marketing network.
Recent Market Developments
Similarly, recent developments have been tracked by the team at Future Market Insights related to companies in the breast reconstruction surgery and treatment space, which are available in the full report.
| Attribute | Details |
|---|---|
| Forecast Period | 2023 to 2033 |
| Historical Data Available for | 2017 to 2022 |
| Market Analysis | USD Million for Value |
| Key Regions Covered | North America; Latin America; Europe; Asia-Pacific excluding Japan; and the Middle East & Africa |
| Key Countries Covered | The USA, Canada, Brazil, Mexico, Argentina, United Kingdom, Germany, Italy, Russia, Spain, France, BENELUX, India, Thailand, Indonesia, Malaysia, Japan, China, South Korea, Australia, New Zealand, Türkiye, GCC Countries, North Africa, and South Africa |
| Key Market Segments Covered | Product, Procedure, Surgery, End-User, and Region |
| Key Companies Profiled | Mentor Worldwide LLC (Johnson & Johnson); Allergan Aesthetics (An AbbVie Company); Sientra; POLYTECH Health & Aesthetics GmbH; GC Aesthetics; Sebbim; Establishment Labs S.A.; Integra Lifesciences; RTI Surgical Holdings; Idel Implant Incorporated; Laboratoires Arion; Silimed; Guangzhou Wanhe Plastic Material Co., Ltd.; Cereplas; Hansbiomed; PMT Corporation; PFM Medical |
| Report Coverage | Market Forecast, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, Strategic Growth Initiatives |
| Pricing | Available upon Request |
The market is valued at USD 901.3 million in 2023.
The growth potential of the market is 5.9% through 2033.
Introduction of 3D-printed implants is expected to create opportunities for players.
Availability of alternative methods like non-surgical procedures is likely to limit market growth.
Surging demand for acellular dermal matrix is likely to provide growth prospects for the market players.
| Estimated Size, 2024 | USD 360.9 million |
|---|---|
| Projected Size, 2034 | USD 593.5 million |
| Value-based CAGR (2024 to 2034) | 5.1% |
| Current Year Value (2023) | USD 19.09 billion |
|---|---|
| Expected Forecast Value (2033) | USD 41.64 billion |
| Projected CAGR (2023 to 2033) | 8.1% |
| Market Value (2022) | USD 2.1 Billion |
|---|---|
| Market Value (2032) | USD 3.6 Billion |
| CAGR (2022 to 2032) | 5.5% |
| Market Value in 2022 | USD 10.2 Billion |
|---|---|
| Market Forecast Value in 2032 | USD 17.9 Billion |
| Growth Rate (2022 to 2032) | 5.8% |
Explore Therapeutic Device Insights
View Reports
Breast Reconstruction Surgery and Treatment Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
